Polaris Group, a pharmaceutical company, has appointed Robert Hoffman as chief financial officer (CFO). Hoffman has joined Polaris from Arena Pharmaceuticals, where he held senior financial positions for more than 13 years. Most recently, Hoffman was vice president of finance and CFO.
In his leadership roles, Hoffman contributed to the success of Arena’s initial public offering in 2000 and other equity, debt and collaborative transactions that totalled nearly US$1.5bn as Arena built a pipeline of drug candidates and completed a Phase 3 pivotal programme for its lead candidate.
Hoffman currently serves as a member of the Financial Accounting Standards Board’s (FASB) small business advisory committee and the steering committee of the Association of Bioscience Financial Officers. In addition, he is a member and former president of the San Diego chapter of Financial Executives International (FEI) and a director of the charitable organisation Day For Change. Hoffman earned a bachelor’s degree in business administration from St Bonaventure University.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.